Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Blood Cancer Journal"
DOI: 10.1038/s41408-019-0219-3
Abstract: In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory… read more here.
Keywords: bendamustine ixazomib; ixazomib dexamethasone; phase;